BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

757 related articles for article (PubMed ID: 18390412)

  • 1. Immunotherapy of hematological malignancies using dendritic cells.
    Van de Velde AL; Berneman ZN; Van Tendeloo VF
    Bull Cancer; 2008 Mar; 95(3):320-6. PubMed ID: 18390412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cellular immunotherapy for hematological malignancies].
    Yasukawa M
    Rinsho Ketsueki; 2008 Oct; 49(10):1460-71. PubMed ID: 18833930
    [No Abstract]   [Full Text] [Related]  

  • 3. DC-based immunotherapy of B-cell malignancies.
    Reichardt VL; Brossart P
    Cytotherapy; 2004; 6(1):62-7. PubMed ID: 14985168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cell-based immunotherapy for the treatment of hematological malignancies.
    Büchler T; Michalek J; Kovarova L; Musilova R; Hajek R
    Hematology; 2003 Apr; 8(2):97-104. PubMed ID: 12745659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idiotypic vaccination in B-cell malignancies.
    Bianchi A; Massaia M
    Mol Med Today; 1997 Oct; 3(10):435-41. PubMed ID: 9358470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel bispecific diabody alphaCD40/alphaCD28 strengthens leukaemic dendritic cell-induced T-cell reactivity.
    Houtenbos I; Santegoets S; Westers TM; Waisfisz Q; Kipriyanov S; Denkers F; Scheper RJ; de Gruijl TD; Ossenkoppele GJ; van de Loosdrecht AA
    Br J Haematol; 2008 Jun; 142(2):273-83. PubMed ID: 18492117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer.
    Santin AD; Bellone S; Underwood LJ; O'Brien TJ; Ravaggi A; Pecorelli S; Cannon MJ
    Minerva Ginecol; 2002 Apr; 54(2):133-44. PubMed ID: 12032451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taming cancer by inducing immunity via dendritic cells.
    Palucka AK; Ueno H; Fay JW; Banchereau J
    Immunol Rev; 2007 Dec; 220():129-50. PubMed ID: 17979844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DC in multiple myeloma immunotherapy.
    Turtle CJ; Brown RD; Joshua DE; Hart DN
    Cytotherapy; 2004; 6(2):128-37. PubMed ID: 15203989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma.
    Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA
    J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DC therapy for prostate cancer.
    Swindle PW; Tepes S; Clements J
    Cytotherapy; 2004; 6(2):164-71. PubMed ID: 15203993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of dendritic cells in cancer immunotherapy.
    Nencioni A; Grünebach F; Schmidt SM; Müller MR; Boy D; Patrone F; Ballestrero A; Brossart P
    Crit Rev Oncol Hematol; 2008 Mar; 65(3):191-9. PubMed ID: 18055210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cellular immunotherapy for hematopoietic malignancies].
    Yasukawa M
    Nihon Rinsho; 2007 Jan; 65 Suppl 1():390-4. PubMed ID: 17474435
    [No Abstract]   [Full Text] [Related]  

  • 14. Identification of hematological malignancy-associated antigens and clinical applications.
    Fujiwara H
    Rinsho Ketsueki; 2009 May; 50(5):340-51. PubMed ID: 19483393
    [No Abstract]   [Full Text] [Related]  

  • 15. Dendritic cell-based immunotherapy.
    Osada T; Clay TM; Woo CY; Morse MA; Lyerly HK
    Int Rev Immunol; 2006; 25(5-6):377-413. PubMed ID: 17169781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cytotoxic T-lymphocytes and the recognition of tumor antigens--an approach to "preventive tumor vaccination?"].
    Peiper M; Goedegebuure PS; Eberlein TJ; Zornig C
    Zentralbl Chir; 1997; 122(3):141-8. PubMed ID: 9206906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cell-based vaccines in breast and gynaecologic cancer.
    Hernando JJ; Park TW; Kuhn WC
    Anticancer Res; 2003; 23(5b):4293-303. PubMed ID: 14666641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell epitope peptide vaccines.
    Elsawa SF; Rodeberg DA; Celis E
    Expert Rev Vaccines; 2004 Oct; 3(5):563-75. PubMed ID: 15485336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?
    Shurin MR; Gregory M; Morris JC; Malyguine AM
    Expert Opin Biol Ther; 2010 Nov; 10(11):1539-53. PubMed ID: 20955111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.